The new assets expand Biocon Biologics’ already robust oncology portfolio, which now includes 17 cancer therapies
Diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma (NHL) in adults, represents 40% of all cases worldwide
Cupid is strengthening its footprint in the GCC region, focusing on supply responsiveness and market proximity
The company announced that it has been granted patent covering “Substituted Ethylamine Fused Heterocyclic Mescaline Derivatives.”
Under his leadership, Chidamide became China’s first original small-molecule anti-tumor innovative drug and the country’s first pharmaceutical product globally licensed out
Lucid-MS represents a potential breakthrough in the treatment of multiple sclerosis
If approved, imlifidase has the potential to transform the kidney transplant landscape by enabling highly sensitized patients to also have access to a potentially life-changing kidney transplant
The portfolio includes foundational patents on the production, composition, and commercial use of NR
FOP is a rare genetic disorder caused by mutations in the ALK2 kinase
Under the agreement, AVT06 is licensed to enter the US market in the fourth quarter of 2026
Subscribe To Our Newsletter & Stay Updated
